Long-Term Low-Carb Diet Efficacious for Treating Dyslipidemia in T2D
By Elana Gotkine HealthDay Reporter
FRIDAY, Aug. 2, 2024 -- For individuals with type 2 diabetes, long-term low-carbohydrate diets (LCD) are efficacious for treatment of dyslipidemia but do not affect glycemic control, according to a review published online July 24 in the Journal of Diabetes Investigation.
Takahiro Ichikawa, from the Kyoto Prefectural University of Medicine in Japan, and colleagues conducted a systematic review to examine the association between long-term LCD and glycemic control in individuals with type 2 diabetes. Six studies met the inclusion criteria.
The researchers found no significant differences in changes in glycated hemoglobin (HbA1c) between long-term LCD and control diets. Furthermore, between long-term and control diets, there were no significant differences in the changes in weight loss, blood pressure, and low-density lipoprotein cholesterol. Compared with control diets, long-term LCD were associated with greater elevation in high-density lipoprotein cholesterol (standardized mean difference, 0.22) and a decrease in triglyceride levels (standardized mean difference, −0.19).
"Long-term LCD might be an important approach in the management of diabetic dyslipidemia in individuals with type 2 diabetes," the authors write. "However, in the present study, long-term LCD were not found to be more effective than control diets in the reduction of HbA1c levels."
Several authors disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted August 2024
Read this next
Many Medicaid Enrollees Have Restricted Access to SGLT2 Inhibitors, GLP-1 Receptor Agonists
WEDNESDAY, April 30, 2025 -- Many Medicaid enrollees with type 2 diabetes have restricted access to cardioprotective medications, including sodium-glucose cotransporter-2...
Sodium-Glucose Cotransporter 2 Inhibitors Increase Risk for Falls in Patients With Diabetes
WEDNESDAY, April 30, 2025 -- Sodium-glucose cotransporter 2 (SGLT2) inhibitor use is an independent risk factor for falls in people with type 2 diabetes, according to a study...
GLP-1 RAs, SGLT2 Inhibitors May Reduce Risk for Alzheimer Disease, Dementia in T2DM
THURSDAY, April 17, 2025 -- Both glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) are associated with a reduced risk...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.